VKTX250110C45500
- 0.21
- 0.000.00%
Viking Therapeutics Newsroom
This Insider Has Just Sold Shares In Viking Therapeutics
Viking Therapeutics Analyst Ratings
H.C. Wainwright Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $102
Express News | Viking Therapeutics Announces Initiation of Phase 2 Venture-Oral Dosing Trial of Vk2735 Tablet Formulation in Patients With Obesity
Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients With Obesity
FDA Issues Draft Guidance on Developing Weight Loss Drugs
Insider Sale: President & CEO of $VKTX (VKTX) Sells 175,490 Shares
Viking Therapeutics, Inc. (VKTX) Stock Sinks As Market Gains: What You Should Know
Express News | Form 144 | Viking Therapeutics(VKTX.US) Officer Proposes to Sell 8.31 Million in Common Stocks
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Why Viking Therapeutics Stock Plummeted by 24% in December
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
VKTX Stock Loses More Than 20% in Six Months: Should You Buy the Dip?
Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years
Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX), Arcutis Biotherapeutics (ARQT) and Viking Therapeutics (VKTX)
Will Viking Therapeutics, Inc. (VKTX) Make You Rich In 2025?
Weight-loss Drugs in 2025, Auto Industry Outlook: Market Domination